Latest Acute Myeloid Leukaemia News

Percheron Therapeutics has received a US FDA Safe to Proceed letter for Vanderbilt Health to begin an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine. The early-stage study will target up to 20 patients with relapsed or refractory AML or AML with MDS.

Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.

Racura Oncology has launched patient enrolment at its first Korean site for the CPACS Phase 1 trial, aiming to accelerate recruitment and validate RC220’s safety and efficacy in a key oncology market.

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Racura Oncology has locked in an underwriting agreement covering nearly 1.84 million expiring options, ensuring up to $2.3 million in fresh capital to back its cancer drug development programs.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.

Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.